Documents

Four CDMO programs advance as a 20-ton fragrance deal targets $20–30M in 2027–2028.

Proprietary plant cell culture drives revenue growth and expansion, with $37–$40M projected this year.

Patented plant cell culture platform drives scalable growth and strong revenue outlook.

Patented cell culture platform secures $20–30M fragrance deal, targets $40M revenue and profitability.

Secured first major CDMO fragrance contract, driving revenue growth and path to 2027 breakeven.

Proprietary plant cell platform and D2C/CDMO engines drive projected $37–40M 2026 revenue.

Q1 revenue up 8% to $8.5M, CDMO and D2C segments advance, 2026 outlook reaffirmed.

Botanical synthesis powers rapid growth in health-focused plant compounds and D2C sales.

Record revenue growth and market leadership achieved through patented botanical synthesis.

Strong revenue growth, margin expansion, and strategic CDMO advances position for 2026 acceleration.

Q3 revenue up 39% to $9.1M, gross margin at 61%, and $30.8M raised for growth initiatives.

Breakthrough in scalable plant exosome production unlocks new high-margin markets and revenue streams.

Q2 2025 revenue up 41% as Botanical Synthesis powers D2C and CDMO growth engines.

Plant cell biotech drives growth with scalable tech, high-margin CDMO, and expanding product lines.

41% revenue growth, 60% gross margin, and new channels drive path to Q4 EBITDA breakeven.

Q1 revenue up 47% to $7.9M, gross margin 58.5%, and major CDMO contract advanced.

Q4 revenue up 62% year-over-year, gross margin at 57%, and strong growth outlook for 2025.

Q3 revenue up 101% to $6.5M, gross margin at 57%, and strong growth in both product and CDMO divisions.